Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 389-400 , July 2010

Statistical consideration for clinical biomarker research in bladder cancer

  • Shahrokh F. Shariat, M.D., Ph.D.

      Affiliations

    • Department of Surgery/Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
    • Department of Urology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-469-363-8500; fax: +1-212-366-4436
    • ,
  • Yair Lotan, M.D.

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • ,
  • Andrew Vickers, M.D.

      Affiliations

    • Department of Surgery/Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
    • ,
  • Pierre I. Karakiewicz, M.D., M.P.H.

      Affiliations

    • University of Montreal, Montreal, Quebec, Canada
    • ,
  • Bernd J. Schmitz-Dräger, M.D.

      Affiliations

    • Department of Urology, University of Erlangen, Erlangen, Germany
    • ,
  • Peter J. Goebell, M.D.

      Affiliations

    • Department of Urology, Euromed Clinic, Fürth, Germany
    • ,
  • Nuria Malats, M.D.

      Affiliations

    • Spanish National Cancer Research Centre, Madrid, Spain

References 

  1. Egawa S, Kuruma H. Search for biomarkers of aggressiveness in bladder cancer. Eur Urol. 2006;50:20–22
  2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145
  3. van Gils MP, Stenman UH, Schalken JA, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol. 2005;48:1031–1041
  4. Shariat SF, Kattan MW, Vickers AJ, et al. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5:1555–1584
  5. Vickers AJ, Lilja H. Cutpoints in clinical chemistry: Time for fundamental reassessment. Clin Chem. 2009;55:15–17
  6. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology. 2010;21:128–138
  7. Schmitz-Drager BJ, Fradet Y, Grossman HB. Bladder cancer markers in patient management: The current perspective. World J Urol. 2008;26:1–3
  8. Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: Technologies and integrative approaches. Trends Biotechnol. 2004;22:411–416
  9. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95
  10. Svatek RS, Lotan Y, Karakiewizc PI, et al. Screening for bladder cancer using urine-based tumor markers. Minerva Urol Nefrol. 2008;60:247–253
  11. Shariat SF, Zippe C, Ludecke G, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma of the bladder. J Urol. 2005;173:1518–1525
  12. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810–816
  13. Herman MP, Svatek RS, Lotan Y, et al. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol. 2008;60:217–235
  14. Goebell PJ, Groshen S, Schmitz-Drager BJ, et al. The International Bladder Cancer Bank: Proposal for a new study concept. Urol Oncol. 2004;22:277–284
  15. Huang HY, Shariat SF, Sun TT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome. Hum Pathol. 2007;38:1703–1713
  16. Schnitt SJ. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr. 2001;(30):22–26
  17. Shariat SF, Karam JA, Walz J, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008;14:3785–3791
  18. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014–1024
  19. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112:315–325
  20. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8:128–136
  21. Andre F, Pusztai L. Molecular classification of breast cancer: Implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006;3:621–632
  22. Grossman HB. Are biomarkers for bladder cancer beneficial?. J Urol. 2010;183:11–12
  23. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52:1601–1609
  24. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol. 2005;6:678–686
  25. Check E. Proteomics and cancer: Running before we can walk?. Nature. 2004;429:496–497
  26. Diamandis EP. Proteomic patterns to identify ovarian cancer: 3 Years on. Expert Rev Mol Diagn. 2004;4:575–577
  27. Dalbagni G, Parekh DJ, Ben-Porat L, et al. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007;99:281–285
  28. Svatek RS, Jeldres C, Karakiewicz PI, et al. Pretreatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate. 2009;69:886–894
  29. Bensalah K, Lotan Y, Karam JA, et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:112–120
  30. Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research (Recent results). Cancer Res. 2003;163:72–84Discussion 264–6
  31. Winget MD, Baron JA, Spitz MR, et al. Development of common data elements: The experience of and recommendations from the early detection research network. Int J Med Inform. 2003;70:41–48
  32. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66(6 Suppl 1):35–63
  33. Goebell PJ, Groshen SL, Schmitz-Drager BJ. Guidelines for development of diagnostic markers in bladder cancer. World J Urol. 2008;26:5–11
  34. Shariat SF, Canto EI, Kattan MW, et al. Beyond prostate-specific antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol. 2004;6:58–72
  35. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027–4034
  36. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: One size does not fit all. J Biopharm Stat. 2009;19:530–542
  37. Shariat SF, Karakiewicz PI. Perspectives on prostate cancer biomarkers. Eur Urol. 2008;54:8–10
  38. Shariat SF, Karakiewicz PI, Roehrborn CG, et al. An updated catalog of prostate cancer predictive tools. Cancer. 2008;113:3075–3099
  39. Shariat SF, Karam JA, Margulis V, et al. New blood-based biomarkers for the diagnosis, staging, and prognosis of prostate cancer. BJU Int. 2008;101:675–683
  40. Steyerberg EW, Harrell FE, Borsboom GJ, et al. Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774–781
  41. Kattan MW. Nomograms introduction. Semin Urol Oncol. 2002;20:79–81
  42. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton, (FL): Chapman and Hall/CRC; 1993;
  43. Kattan MW. Comparison of Cox regression with other methods for determining prediction models and nomograms. J Urol. 2003;170(6 Pt 2):S6–S9Discussion S10
  44. Steyerberg EW, Bleeker SE, Moll HA, et al. Internal and external validation of predictive models: A simulation study of bias and precision in small samples. J Clin Epidemiol. 2003;56:441–447
  45. Steyerberg EW, Harrell FE, Goodman PH. Neural networks, logistic regression, and calibration. Med Decis Making. 1998;18:349–350
  46. Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12:7369–7373
  47. Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101:114–119
  48. Lotan Y. Role of biomarkers to predict outcomes and response to therapy. Urol Oncol. 2010;28:97–101
  49. Vickers AJ, Elkin EB. Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making. 2006;26:565–574
  50. Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Making. 2008;8:53–70
  51. Vickers AJ. Decision-analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat. 2008;62:314–320
  52. Elkin EB, Vickers AJ, Kattan MW. Primer: Using decision-analysis to improve clinical decision making in urology. Nat Clin Pract Urol. 2006;3:439–448
  53. Shariat SF, Casella R, Wians FH, et al. Risk stratification for bladder tumor recurrence, stage, and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol. 2004;45:304–313author reply 313
  54. Elstein AS. Heuristics and biases: Selected errors in clinical reasoning. Acad Med. 1999;74:791–794
  55. Vlaev I, Chater N. Game relativity: How context influences strategic decision making. J Exp Psychol Learn Mem Cogn. 2006;32:131–149
  56. Hogarth RM, Karelaia N. Heuristic and linear models of judgment: Matching rules and environments. Psychol Rev. 2007;114:733–758
  57. Ross PL, Gerigk C, Gonen M, et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 2002;20:82–88
  58. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562–1568
  59. Specht MC, Kattan MW, Gonen M, et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: Clinicians vs. nomogram. Ann Surg Oncol. 2005;12:654–659
  60. Walz J, Gallina A, Perrotte P, et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007;100:1254–1258
  61. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006;176(4 Pt 1):1354–1361Discussion 1361–2.
  62. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006;50:1254–1260Discussion 1261–2
  63. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12:6663–6676
  64. Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res. 2008;14:4400–4407
  65. Shariat SF, Margulis V, Lotan Y, et al. Nomograms for bladder cancer. Eur Urol. 2008;54:41–53
  66. Lerner SP, Bochner B, Kibel AS. The use and abuse of data: Nomograms and talking to patients about clinical medicine. Urol Oncol. 2007;25:333–337
  67. Begg CB, Cramer LD, Venkatraman ES, et al. Comparing tumor staging and grading systems: A case study and a review of the issues, using thymoma as a model. Stat Med. 2000;19:1997–2014
  68. Vickers AJ, Jang K, Sargent D, et al. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer. 2008;112:1862–1868
  69. Vickers AJ, Kattan MW, Daniel S. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials. 2007;8:14–25
  70. Vickers AJ, Cronin AM, Kattan MW, et al. Clinical benefits of a multivariate prediction model for bladder cancer: A decision analytic approach. Cancer. 2009;115:5460–5469
  71. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24:3967–3972
  72. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–1184
  73. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466

PII: S1078-1439(10)00053-0

doi: 10.1016/j.urolonc.2010.02.011

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 4 , Pages 389-400 , July 2010

Article Tools

* Image Usage & Resolution